Key Highlights
- Medable partners with Masimo to integrate award-winning pulse oximetry technology in clinical trials.
- Masimo’s MightySat® Rx pulse oximeter enhances Medable’s evidence-generation platform for oncology trials.
- The partnership reduces patient travel burdens and enables comprehensive data capture for deeper analysis.
- Medable’s flexible platform supports scalability and data aggregation for diverse clinical trial needs.
Source: Business Wire
Notable Quotes
- “Medable has always been a leader in digital and decentralized clinical trials, so we are excited to work with a forward-thinking organization with the ambition and ability to transform research.” – Dr. Daniel Cantillon, Chief Medical Officer at Masimo
- “Masimo’s SET® pulse oximetry is sensitive enough to capture key vitals on the very ill like cancer patients, plus it works on all skin tones, all ages, and is easy to use.” – Musaddiq Khan, Vice President of Digital Outcomes and TA Strategy at Medable
SoHC's Take
The partnership between Medable and Masimo marks a significant advancement in the realm of clinical trials. By integrating Masimo’s highly trusted pulse oximeter technology into Medable’s digital platform, the collaboration addresses a critical need for reliable, non-invasive monitoring tools in decentralized trials. This move not only alleviates the logistical challenges faced by patients, particularly those with severe illnesses like cancer, but also enhances the overall quality and scope of data collected. Medable’s continued innovation and strategic alliances underscore its pivotal role in transforming clinical research and accelerating the delivery of effective therapies to patients worldwide.
